Processing

Please wait...

Settings

Settings

1. US20150141402 - Purine derivatives

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. A compound of formula (IIIa):
wherein
R 1 is hydrogen, C 1-C 6 alkyl, C 2-C 6 alkenyl, C 2-C 6 alkynyl, C 3-C 6 cycloalkyl, 4-6 membered heterocycloalkyl, or 4-6 membered heteroaryl, wherein the C 1-C 6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, and C 1-C 3 alkoxy, further wherein the C 3-C 6 cycloalkyl, the 4-6 membered heterocycloalkyl, and the 4-6 membered heteroaryl are each independently optionally substituted by one, two or three substituents selected from the group consisting of C 1-C 3 alkyl, hydroxy, and C 1-C 3 alkoxy;
R 2 and R 5 are each independently hydrogen, halogen, cyano, difluoromethyl, trifluoromethyl, C 1-C 6 alkyl, C 2-C 6 alkenyl, C 2-C 6 alkynyl, C 1-C 6 alkoxy, —N(R 10)(R 11), C 3-C 5 cycloalkyl, or 4-6 membered heterocycloalkyl, wherein the C 1-C 6 alkyl is optionally substituted by one, two or three substituents selected from the group consisting of halogen, hydroxy, C 1-C 6 alkoxy, and —N(R 12)(R 13),
provided that at least one of R 2 or R 5 is hydrogen;
R 3 is hydrogen, halogen, C 1-C 6 alkyl, C 2-C 6 alkynyl, C 1-C 6 alkoxy, C 3-C 7 cycloalkyl, or 3-7 membered heterocycloalkyl, wherein the C 1-C 6 alkyl and the C 1-C 6 alkoxy are each optionally substituted by one, two or three R 14 groups, and further wherein the C 3-C 7 cycloalkyl and the 3-7 membered heterocycloalkyl are each optionally substituted by one, two or three R 15 groups;
R 6 and R 8 are each independently hydrogen, halogen, cyano, hydroxy, difluoromethyl, trifluoromethyl, C 1-C 3 alkyl, C 1-C 3 alkoxy, or C 3-C 5 cycloalkyl, wherein the C 1-C 3 alkyl is optionally substituted by hydroxy, difluoromethyl, trifluoromethyl, C 1-C 3 alkoxy, or C 3-C 5 cycloalkyl;
R 7 is

(MOL) (CDX)
G is —NR 18—;
R 10 and R 11 are each independently hydrogen or C 1-C 6 alkyl; or R 10 and R 11 together with the nitrogen to which they are attached, may combine to form a 4-7 membered heterocycloalkyl ring, when R 10 and R 1l are each C 1-C 3 alkyl, wherein the 4-7 membered heterocycloalkyl ring formed is optionally substituted by one, two, three or four R 15 groups;
R 12 and R 13 are each independently hydrogen or C 1-C 3 alkyl;
each R 14 is independently halogen, cyano, C 1-C 3 alkyl, hydroxy, C 1-C 6 alkoxy,—N(R 19)(R 20), —CON(R 21)(R 22), or 3-7 membered heterocycloalkyl, wherein the 3-7 membered heterocycloalkyl is optionally substituted by one, two, three or four R 15 groups;
each R 15 is independently halogen, C 1-C 3 alkyl, hydroxy, C 1-C 6 alkoxy, —NH 2, —NHCH 3, or —N(CH 3) 2;
R 16 and R 17 are each independently hydrogen or C 1-C 6 alkyl, wherein the C 1-C 6 alkyl is optionally substituted by —N(R 23)(R 24),
provided that R 16 and R 17 may form C 3-C 5 cycloakyl ring;
R 18 is hydrogen or C 1-C 3 alkyl;
each R 19, R 20, R 21, R 22, R 23, and R 24 is independently hydrogen or C 1-C 3 alkyl;
n is 0, 1, or 2; and
p is 0, 1, or 2; or
a pharmaceutically acceptable salt thereof.
2. The compound or salt of claim 1, wherein n is 0.
3. The compound or salt of claim 1, wherein R 6 and R 8 are each independently hydrogen, halogen, C 1-C 3 alkyl, or C 1-C 3 alkoxy.
4. The compound or salt of claim 1, wherein R 6 is hydrogen, fluorine, methyl, or methoxy.
5. The compound or salt of claim 1, wherein R 6 is fluorine.
6. The compound or salt of claim 1, wherein R 8 is hydrogen, fluorine, or methyl.
7. The compound or salt of claim 1, having formula (IIIb):
8. A compound, which is
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
10. A pharmaceutical composition comprising a compound, which is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
11. A method of treating lung cancer in a mammal comprising administering to the mammal an amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating lung cancer.